Company Profile
Lyra Therapeutics Stock Price, News & Catalysts
- Ticker:
- LYRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.01 USD (+2400.00%)
Close
Last updated: August 21, 2026
—
Market cap
Why the stock is moving
As of Aug 21, 2026, LYRA closed up 2400.0% at $0.0100. No new same-company headline was identified in the current news window.
Company overview
Business overview
Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lyra sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, delivery technology, and the ability to build a niche ENT franchise.
Position Within the Biotechnology Landscape
Lyra is a niche ENT catalyst name whose stock is driven by clinical and regulatory progress.
Future catalysts
- Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing. The story is about procedure adoption more than binary events.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lyra Therapeutics (LYRA)?
Lyra Therapeutics (LYRA) most recently closed at 0.01 USD, a +2400.00% move versus the previous session.
What does Lyra Therapeutics do?
Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.
On which exchange is LYRA stock listed?
Lyra Therapeutics (LYRA) is associated with NASDAQ, United States, Biopharma.
What is Lyra?
Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing.
Which conditions is Lyra Therapeutics targeting with Lyra?
Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing.
How does Lyra Therapeutics describe recent progress with Lyra?
Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing.
What is Therapeutics?
Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease.
What should investors watch for with Therapeutics?
Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing. The story is about procedure adoption more than binary events.